{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:14:51Z","timestamp":1754144091883,"version":"3.41.2"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.amjms.2025.04.007","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T11:02:01Z","timestamp":1745233321000},"page":"109-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The management of antiplatelet therapy in patients with coronary artery disease and thrombocytopenia"],"prefix":"10.1016","volume":"370","author":[{"given":"Yal\u00e7\u0131n","family":"Velibey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Servet","family":"Altay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Bolca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.amjms.2025.04.007_bib0001","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.amjms.2025.04.007_bib0002","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. ESC Scientific Document Group","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.amjms.2025.04.007_bib0003","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjms.2025.04.007_bib0004","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","article-title":"Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristic sof the platelet inhibition and patient outcomes (PLATO) trial","volume":"157","author":"James","year":"2009","journal-title":"Am Heart J"},{"issue":"14","key":"10.1016\/j.amjms.2025.04.007_bib0005","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.amjms.2025.04.007_bib0006","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjms.2025.04.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead076","article-title":"Safety of cangrelor and transition to oral P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study","volume":"3","author":"De Luca","year":"2023","journal-title":"Eur Heart J Open"},{"issue":"20","key":"10.1016\/j.amjms.2025.04.007_bib0008","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.3390\/jcm12206422","article-title":"Recommendations for the clinical approach to immune thrombocytopenia: Spanish ITP Working Group (GEPTI)","volume":"12","author":"Mingot-Castellano","year":"2023","journal-title":"J Clin Med"},{"issue":"22","key":"10.1016\/j.amjms.2025.04.007_bib0009","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.3390\/jcm11226679","article-title":"Special Issue \u201cadvances in thrombocytopenia","volume":"11","author":"Ji","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjms.2025.04.007_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101141","article-title":"The many facets of immune-mediated thrombocytopenia: principles of immunobiology and immunotherapy","volume":"63","author":"Moulinet","year":"2024","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.amjms.2025.04.007_bib0011","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/jcm13041012","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: clinicopathologic features and new perspectives on Anti-PF4 antibody-mediated disorders","volume":"13","author":"Zhang","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjms.2025.04.007_bib0012","article-title":"Percutaneous coronary intervention in acute coronary syndrome with mild-to-moderate thrombocytopenia","author":"Ye","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjms.2025.04.007_bib0013","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.amjcard.2008.08.055","article-title":"GRACE Investigators thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE])","volume":"103","author":"Gore","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjms.2025.04.007_bib0014","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ahj.2014.04.010","article-title":"Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome","volume":"168","author":"Vora","year":"2014","journal-title":"Am Heart J"},{"issue":"47","key":"10.1016\/j.amjms.2025.04.007_bib0015","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","article-title":"The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum","volume":"38","author":"McCarthy","year":"2017","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.amjms.2025.04.007_bib0016","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1378\/chest.13-0121","article-title":"PROTECT collaborators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes","volume":"144","author":"Williamson","year":"2013","journal-title":"Chest"},{"issue":"23","key":"10.1016\/j.amjms.2025.04.007_bib0017","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.amjms.2025.04.007_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101222","article-title":"Immune thrombocytopenia: pathophysiology and impacts of Romiplostim treatment","volume":"67","author":"Semple","year":"2024","journal-title":"Blood Rev"},{"issue":"18","key":"10.1016\/j.amjms.2025.04.007_bib0019","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/CIRCULATIONAHA.108.827162","article-title":"Incidence and prognostic significance of thrombocytopenia developed during acutecoronary syndrome in contemporary clinical practice","volume":"119","author":"Wang","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.amjms.2025.04.007_bib0020","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cjca.2015.05.020","article-title":"Effect of baseline thrombocytopenia on ischemic outcomes in patients with acute coronary syndromes who undergo percutaneous coronary intervention","volume":"32","author":"Yadav","year":"2016","journal-title":"Can J Cardiol"},{"issue":"18","key":"10.1016\/j.amjms.2025.04.007_bib0021","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.jcin.2018.05.033","article-title":"Impact of chronic thrombocytopenia on In-hospital outcomes after percutaneous coronary intervention","volume":"11","author":"Ayoub","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjms.2025.04.007_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1348941","article-title":"A practical guide to the management of immune thrombocytopenia co-existing with acute coronary syndrome","volume":"11","author":"Rahhal","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.amjms.2025.04.007_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25040","article-title":"Pan-pseudothrombocytopenia: an unusual case of platelet clumping","author":"Elmariah","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.amjms.2025.04.007_bib0024","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/ajcp\/110.2.178","article-title":"IgG platelet antibodies in EDTA-dependent pseudothrombocytopenia bind to platelet membrane glycoprotein IIb","volume":"110","author":"Fiorin","year":"1998","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"10.1016\/j.amjms.2025.04.007_bib0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/00365519709055287","article-title":"Screening for EDTA-dependent deviations in platelet counts and abnormalities in platelet distribution histograms in pseudothrombocytopenia","volume":"57","author":"Bartels","year":"1997","journal-title":"Scand J Clin Lab Invest"},{"issue":"3","key":"10.1016\/j.amjms.2025.04.007_bib0026","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1002\/ajh.25379","article-title":"Drug-induced thrombocytopenia: 2019 update of clinical and laboratory data","volume":"94","author":"Mitta","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.amjms.2025.04.007_bib0027","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1002\/ajh.26482","article-title":"Drug (vaccine)-induced thrombocytopenia 2021: diversity of pathogenesis and clinical features","volume":"97","author":"Nusrat","year":"2022","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.amjms.2025.04.007_bib0028","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3390\/jcm13082380","article-title":"Linezolid-associated thrombocytopenia: assessment of risk factors in patients without hemato-oncologic diseases","volume":"13","author":"Thabit","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.amjms.2025.04.007_bib0029","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13256-023-04169-5","article-title":"Severe thrombocytopenia induced by tirofiban after percutaneous coronary intervention: a case report","volume":"17","author":"Wang","year":"2023","journal-title":"J Med Case Rep"},{"issue":"1","key":"10.1016\/j.amjms.2025.04.007_bib0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1538-7836.2011.04563.x","article-title":"Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention","volume":"10","author":"Campo","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.amjms.2025.04.007_bib0031","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.amjcard.2018.07.033","article-title":"Safety of diagnostic and therapeutic cardiac catheterization in cancer patients with acute coronary syndrome and chronic thrombocytopenia","volume":"122","author":"Iliescu","year":"2018","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.amjms.2025.04.007_bib0032","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.amjms.2025.04.007_bib0033","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/mhj.2000.107554","article-title":"Thrombocytopenia complicating treatment with intravenous glycoprotein IIb\/IIIa receptor inhibitors: a pooled analysis","volume":"140","author":"Dasgupta","year":"2000","journal-title":"Am Heart J"},{"issue":"13","key":"10.1016\/j.amjms.2025.04.007_bib0034","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.292.13.1555","article-title":"Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes","volume":"292","author":"Rao","year":"2004","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.amjms.2025.04.007_bib0035","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jama.2014.980","article-title":"Patterns and outcomes of red blood cell transfusion in patients undergoing percutaneous coronary intervention","volume":"311","author":"Sherwood","year":"2014","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.amjms.2025.04.007_bib0036","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jcin.2009.05.004","article-title":"Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial","volume":"2","author":"Nikolsky","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.amjms.2025.04.007_bib0037","doi-asserted-by":"crossref","first-page":"746","DOI":"10.7326\/0003-4819-159-11-201312030-00007","article-title":"Treatment of anemia in patients with heart disease: a systematic review","volume":"159","author":"Kansagara","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjms.2025.04.007_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002042.pub3","article-title":"Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion","volume":"4","author":"Carson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.amjms.2025.04.007_bib0039","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/2013.jamainternmed.1001","article-title":"Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis","volume":"173","author":"Chatterjee","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.amjms.2025.04.007_bib0040","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.amjcard.2011.06.014","article-title":"Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study)","volume":"108","author":"Cooper","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjms.2025.04.007_bib0041","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ahj.2008.01.009","article-title":"CRUSADE Investigators. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes","volume":"155","author":"Alexander","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjms.2025.04.007_bib0042","doi-asserted-by":"crossref","first-page":"h1354","DOI":"10.1136\/bmj.h1354","article-title":"Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis","volume":"350","author":"Holst","year":"2015","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.amjms.2025.04.007_bib0043","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1403612","article-title":"TITRe2 Investigators. Liberal or restrictive transfusion after cardiac surgery","volume":"372","author":"Murphy","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.amjms.2025.04.007_bib0044","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ccd.26379","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.amjms.2025.04.007_bib0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1067\/mhj.2000.108239","article-title":"Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel in steadofaspirin. CAPRIE investigators","volume":"140","author":"Bhatt","year":"2000","journal-title":"Am Heart J"},{"issue":"20","key":"10.1016\/j.amjms.2025.04.007_bib0046","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjms.2025.04.007_bib0047","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1111\/jth.14282","article-title":"Subcommittee on Platelet Physiology. Laboratory monitoring of P2Y(12) inhibitors: communication from the SSC of the ISTH","volume":"16","author":"Frelinger","year":"2018","journal-title":"J Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.amjms.2025.04.007_bib0048","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3171\/2012.9.JNS112286","article-title":"Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage","volume":"118","author":"Li","year":"2013","journal-title":"J Neurosurg."},{"issue":"3","key":"10.1016\/j.amjms.2025.04.007_bib0049","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/jcm14030838","article-title":"Antiplatelet therapy in low-platelet-count patients after percutaneous coronary intervention for acute coronary syndromes","volume":"14","author":"Paciullo","year":"2025","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.amjms.2025.04.007_bib0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCINTERVENTIONS.111.967208","volume":"5","author":"Mahla","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"issue":"24","key":"10.1016\/j.amjms.2025.04.007_bib0051","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2010.03.108","article-title":"Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery","volume":"56","author":"Kwak","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.amjms.2025.04.007_bib0052","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.jacc.2010.01.039","article-title":"The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions","volume":"55","author":"Rao","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.amjms.2025.04.007_bib0053","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCINTERVENTIONS.113.000433","article-title":"Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention","volume":"6","author":"Ndrepepa","year":"2013","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.amjms.2025.04.007_bib0054","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.001645","article-title":"Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis","volume":"8","author":"Kwok","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"24","key":"10.1016\/j.amjms.2025.04.007_bib0055","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2012.06.017","article-title":"Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study","volume":"60","author":"Romagnoli","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"9775","key":"10.1016\/j.amjms.2025.04.007_bib0056","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(11)60404-2","article-title":"Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syn dromes (RIVAL): a randomised, parallel group, multicentre trial","volume":"377","author":"Jolly","year":"2011","journal-title":"Lancet"},{"issue":"9986","key":"10.1016\/j.amjms.2025.04.007_bib0057","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/S0140-6736(15)60292-6","article-title":"Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial","volume":"385","author":"Valgimigli","year":"2015","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.amjms.2025.04.007_bib0058","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/eurheartj\/ehx048","article-title":"Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation","volume":"38","author":"Vranckx","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjms.2025.04.007_bib0059","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjcard.2021.06.034","article-title":"Cost-effectiveness of radial access percutaneous coronary intervention in acute coronary syndrome","volume":"156","author":"Lee","year":"2021","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1016\/j.amjms.2025.04.007_bib0060","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"LEADERS FREE investigators. Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.amjms.2025.04.007_bib0061","first-page":"961","article-title":"LEADERS FREE Investigators. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study","volume":"38","author":"Naber","year":"2017","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.amjms.2025.04.007_bib0062","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.amjms.2025.04.007_bib0063","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.amjms.2025.04.007_bib0064","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood-2018-08-868406","article-title":"Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score","volume":"132","author":"Balitsky","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.amjms.2025.04.007_bib0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"suppl 2","key":"10.1016\/j.amjms.2025.04.007_bib0066","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.amjms.2025.04.007_bib0067","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.mbc.0000172694.85233.a8","article-title":"Venousandarterial thrombosis following administration of intravenous immunoglobulins","volume":"16","author":"Paran","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"10.1016\/j.amjms.2025.04.007_bib0068","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2146\/ajhp100673","article-title":"Deep veinthrombosis associated with a single dose of romiplostim in a high-risk patient","volume":"69","author":"PrzespoE","year":"2012","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"10.1016\/j.amjms.2025.04.007_bib0069","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.medcli.2015.03.014","article-title":"Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials","volume":"145","author":"Catal\u00b4a-L\u00b4 opez","year":"2015","journal-title":"Med Clin"},{"issue":"48","key":"10.1016\/j.amjms.2025.04.007_bib0070","doi-asserted-by":"crossref","first-page":"e5098","DOI":"10.1097\/MD.0000000000005098","article-title":"Long-term complications of splenectomy in adult immune thrombocytopenia","volume":"95","author":"Thai","year":"2016","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.amjms.2025.04.007_bib0071","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood.V77.1.31.31","article-title":"High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura","volume":"77","author":"Cortelazzo","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2025.04.007_bib0072","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/963506","article-title":"Comorbidities of idiopathic thrombocytopenic purpura: a population based study","volume":"2009","author":"Feudjo-Tepie","year":"2009","journal-title":"Adv Hematol"},{"issue":"4","key":"10.1016\/j.amjms.2025.04.007_bib0073","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/ejh.12777","article-title":"Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis","volume":"97","author":"Doobaree","year":"2016","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.amjms.2025.04.007_bib0074","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1001\/archinte.160.11.1630","article-title":"The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts","volume":"160","author":"Cohen","year":"2000","journal-title":"Arch Intern Med"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925009863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925009863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T07:52:10Z","timestamp":1752565930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962925009863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0002962925009863"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2025.04.007","relation":{},"ISSN":["0002-9629"],"issn-type":[{"type":"print","value":"0002-9629"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The management of antiplatelet therapy in patients with coronary artery disease and thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2025.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}